CARA Cara Therapeutics Inc
Price (delayed)
$5.1
Market cap
$23.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$15.53
Enterprise value
$29.87M
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is
Highlights
The quick ratio has surged by 162% year-on-year and by 139% since the previous quarter
Cara Therapeutics's EPS has increased by 41% YoY and by 26% from the previous quarter
Cara Therapeutics's equity has plunged by 108% YoY
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
Key stats
What are the main financial stats of CARA
Market
Valuations
Earnings
Shares outstanding
4.57M
Market cap
$23.33M
Enterprise value
$29.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.19
Revenue
$7.14M
Gross profit
$6.52M
Operating income
-$65.62M
Net income
-$70.87M
EBIT
-$62.79M
EBITDA
-$61.83M
Free cash flow
-$61.96M
Per share
Balance sheet
Liquidity
EPS
-$15.53
EPS diluted
-$15.53
Free cash flow per share
-$13.58
Book value per share
-$1
Revenue per share
$1.56
TBVPS
$9.61
Total assets
$43.83M
Total liabilities
$48.42M
Debt
$44.45M
Equity
-$4.59M
Working capital
$39.86M
Debt to equity
-9.68
Current ratio
11.03
Quick ratio
10.67
Net debt/EBITDA
-0.11
Margins
Efficiency
Dividend
EBITDA margin
-866.4%
Gross margin
91.3%
Net margin
-993%
Operating margin
-919.4%
Return on assets
-110%
Return on equity
-755.6%
Return on invested capital
-112.6%
Return on capital employed
-157.6%
Return on sales
-879.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CARA stock price
How has the Cara Therapeutics stock price performed over time
Intraday
3.24%
1 week
-7.74%
1 month
6.69%
1 year
-53.76%
YTD
-16.67%
QTD
0.59%
Financial performance
How have Cara Therapeutics's revenue and profit performed over time
Revenue
$7.14M
Gross profit
$6.52M
Operating income
-$65.62M
Net income
-$70.87M
Gross margin
91.3%
Net margin
-993%
CARA's net margin has dropped by 76% year-on-year but it is up by 10% since the previous quarter
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
Cara Therapeutics's operating margin has plunged by 59% YoY but it has increased by 14% from the previous quarter
CARA's gross profit has plunged by 56% YoY and by 13% from the previous quarter
Growth
What is Cara Therapeutics's growth rate over time
Valuation
What is Cara Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.19
Cara Therapeutics's EPS has increased by 41% YoY and by 26% from the previous quarter
Cara Therapeutics's equity has plunged by 108% YoY
CARA's P/S is 70% below its 5-year quarterly average of 10.4 but 26% above its last 4 quarters average of 2.5
The revenue has dropped by 66% year-on-year and by 18% since the previous quarter
Efficiency
How efficient is Cara Therapeutics business performance
Cara Therapeutics's return on equity has shrunk by 96% QoQ
Cara Therapeutics's ROS has plunged by 56% YoY but it has increased by 14% from the previous quarter
CARA's return on invested capital is up by 36% year-on-year and by 15% since the previous quarter
CARA's ROA is down by 23% YoY but it is up by 2.2% QoQ
Dividends
What is CARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CARA.
Financial health
How did Cara Therapeutics financials performed over time
The total assets is 9% less than the total liabilities
The quick ratio has surged by 162% year-on-year and by 139% since the previous quarter
Cara Therapeutics's current ratio has soared by 143% YoY and by 131% from the previous quarter
The company's debt to equity has shrunk by 116% QoQ
Cara Therapeutics's equity has plunged by 108% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.